JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

JNJ

240

+0.98%↑

UNH

276.41

+2.98%↑

TMO

542.03

+0.18%↑

ABT

110.82

+1.61%↑

ISRG

487.26

+2.36%↑

Search

Innoviva Inc

Fermé

SecteurSoins de santé

21.75 1.26

Résumé

Variation du prix de l'action

24h

Actuel

Min

21.71

Max

21.89

Chiffres clés

By Trading Economics

Revenu

26M

90M

Ventes

7.5M

108M

P/E

Moyenne du Secteur

13.374

84.243

Marge bénéficiaire

83.403

Employés

127

EBITDA

25M

108M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+76.61% upside

Dividendes

By Dow Jones

Prochains Résultats

24 févr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

519M

1.7B

Ouverture précédente

20.49

Clôture précédente

21.75

Sentiment de l'Actualité

By Acuity

25%

75%

45 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Strong Bullish Evidence

Innoviva Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

8 févr. 2026, 23:57 UTC

Market Talk

Uranium Outlook Heats Up on Rising Demand, Uncertain Supply -- Market Talk

8 févr. 2026, 23:47 UTC

Market Talk

Gold Rises Amid Growing U.S.-Iran Tensions -- Market Talk

8 févr. 2026, 23:43 UTC

Market Talk

Nikkei Likely to Rise Sharply After Takaichi's Election Win -- Market Talk

8 févr. 2026, 23:34 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

8 févr. 2026, 23:34 UTC

Market Talk

Landslide Election Victory of Japan's LDP Positive for Risk Assets -- Market Talk

8 févr. 2026, 23:26 UTC

Market Talk

Yen Skittish; Nikkei Jumps On LDP Landslide -- Market Talk

8 févr. 2026, 22:55 UTC

Résultats

DBS Group 4Q Net S$2.36B Vs. Net S$2.62B >D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Group 4Q Net Interest Income S$3.59B Vs. S$3.83B>D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Board Proposes 4Q Dividend of 66 Singapore Cents/share>D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Group: 2025 Total Dividend at S$3.06/share >D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Group 4Q Net Weighed by Higher Tax Expense, Absence of Non-Recurring Gains Recrorded Last Year >D05.SG

8 févr. 2026, 22:55 UTC

Résultats

DBS Group 4Q Total Income S$5.33B Vs. S$5.51B>D05.SG

8 févr. 2026, 21:43 UTC

Market Talk

FX Intervention Watch Resumes After Japan Election Result -- Market Talk

8 févr. 2026, 21:16 UTC

Market Talk

Right Of Australian Politics Reshaped as One Nation Surges -- Market Talk

8 févr. 2026, 21:15 UTC

Market Talk

Japan's Election Outcome to Revive Takaichi Trade -- Market Talk

7 févr. 2026, 09:20 UTC

Market Talk

Financial Services Roundup: Market Talk

7 févr. 2026, 09:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

7 févr. 2026, 05:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

7 févr. 2026, 02:46 UTC

Acquisitions, Fusions, Rachats

Big Money, High Anxiety -- Barrons.com

6 févr. 2026, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

6 févr. 2026, 21:50 UTC

Market Talk

Financial Services Roundup: Market Talk

6 févr. 2026, 21:40 UTC

Acquisitions, Fusions, Rachats

Verizon Insiders Rarely Sell Company Stock. This Insider Just Did. -- Barrons.com

6 févr. 2026, 21:22 UTC

Market Talk

Mexico's Inflation Seen Accelerating in January -- Market Talk

6 févr. 2026, 21:17 UTC

Résultats

Toyota Smashes Earnings Estimates. It's Getting a New CEO. -- Barrons.com

6 févr. 2026, 21:15 UTC

Market Talk

Global Commodities Roundup: Market Talk

6 févr. 2026, 21:14 UTC

Acquisitions, Fusions, Rachats

Justice Department Casts Wide Net on Netflix's Business Practices in Merger Probe -- Update

6 févr. 2026, 21:13 UTC

Résultats

How the Software Panic Hit BDC Stocks -- and Why Some Might Be Worth Buying -- Barrons.com

6 févr. 2026, 21:13 UTC

Résultats

Amazon, Strategy, Robinhood, Novo Nordisk, Molina, Stellantis, Hub Group, and More Stock Market Movers -- Barrons.com

6 févr. 2026, 21:04 UTC

Market Talk

Gold Closes Out Volatile Week on Higher Note -- Market Talk

6 févr. 2026, 20:34 UTC

Résultats

Tech Had an Awful Earnings Season. Other Stocks Are Saving the Day. -- Barrons.com

Comparaison

Variation de prix

Innoviva Inc prévision

Objectif de Prix

By TipRanks

76.61% hausse

Prévisions sur 12 Mois

Moyen 38.5 USD  76.61%

Haut 46 USD

Bas 31 USD

Basé sur 2 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

2 ratings

2

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

18.57 / 18.75Support & Résistance

Court Terme

Strong Bullish Evidence

Moyen Terme

Weak Bullish Evidence

Long Terme

Neutral Evidence

Sentiment

By Acuity

45 / 352Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Inférieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Innoviva Inc

Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.
help-icon Live chat